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Background: Design of effective vaccines against the human immunodeficiency virus (HIV-1) continues to present
formidable challenges. However, individuals who are exposed HIV-1 but do not get infected may reveal correlates
of protection that may inform on effective vaccine design. A preliminary gene expression analysis of HIV resistant
female sex workers (HIV-R) suggested a high expression CD26/DPPIV gene. Previous studies have indicated an anti-
HIV effect of high CD26/DPPIV expressing cells in vitro. Similarly, high CD26/DPPIV protein levels in vivo have been
shown to be a risk factor for type 2 diabetes. We carried out a study to confirm if the high CD26/DPPIV gene
expression among the HIV-R were concordant with high blood protein levels and its correlation with clinical type 2
diabetes and other perturbations in the insulin signaling pathway.
Results: A quantitative CD26/DPPIV plasma analysis from 100 HIV-R, 100 HIV infected (HIV +) and 100 HIV negative
controls (HIV Neg) showed a significantly elevated CD26/DPPIV concentration among the HIV-R group (mean 1315
ng/ml) than the HIV Neg (910 ng/ml) and HIV + (870 ng/ml, p < 0.001). Similarly a FACs analysis of cell associated
DPPIV (CD26) revealed a higher CD26/DPPIV expression on CD4+ T-cells derived from HIV-R than from the HIV+
(90.30% vs 80.90 p = 0.002) and HIV Neg controls (90.30% vs 82.30 p < 0.001) respectively. A further comparison of
the mean fluorescent intensity (MFI) of CD26/DPPIV expression showed a higher DPP4 MFI on HIV-R CD4+ T cells
(median 118 vs 91 for HIV-Neg, p = 0.0003). An evaluation for hyperglycemia, did not confirm Type 2 diabetes but
an impaired fasting glucose condition (5.775 mmol/L). A follow-up quantitative PCR analysis of the insulin signaling
pathway genes showed a down expression of NFB, a central mediator of the immune response and activator of
HIV-1 transcription.
Conclusion: HIV resistant sex workers have a high expression of CD26/DPPIV in tandem with lowered immune
activation markers. This may suggest a novel role for CD26/DPPIV in protection against HIV infection in vivo.
Background
The disease AIDS ranks as one of the most devastating
scourges of mankind. Since it was identified in 1983
more than 30 million people have died and an estimated
33 million currently live with the virus [1]. The majority
of HIV infections occur in Sub-Saharan Africa, where in
some countries prevalence rates of more than 40% have
been documented among antenatal clinic attendees [2].
Despite progress made with antiretroviral therapy, less
than a half of those requiring treatment receive it and
new infections far outpace those on therapy [3]. Similar
to previous viral epidemics, prevention through vaccina-
tion is believed to be the best approach. However sev-
eral factors including HIVs ability to integrate itself to
the host genome and to constantly mutate challenge the
design of a safe and effective vaccine. More critically, a
sufficient understanding of the immune correlates of
protection from HIV infection and disease remains
unresolved.
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any medium, provided the original work is properly cited.Individuals who though highly exposed to HIV but do
not get infected (HIV R) provide an opportunity to bet-
ter understand what mediates HIV protection. HIV R
populations have been identified among intravenous
drug users,[4], children born to HIV infected mothers
[5,6], discordant couples [7], and commercial sex work-
ers [8]. Of the various investigations conducted on HIV
R, the Nairobi commercial sex worker cohort has pro-
vided vital clues for the understanding of correlates for
protection against HIV infection. With more than 25
years of follow-up, this population has provided compel-
ling evidence that HIV resistance is biologically
mediated. The 32 base pair deletion in the CCR5 gene
(CCR5 Δ32), which has been reported in Caucasian
populations to be responsible for cellular resistance to
HIV, has not been observed in this cohort nor have
polymorphisms in other cytokine regions reported else-
where to be connected to HIV resistance [9]. Although
cytotoxic T-cell responses and HIV specific mucosal IgA
have been noted in the Nairobi cohort [10], controversy
surrounds whether they exert a protective effect or
reflect a prior exposure to HIV [11]. A genetic basis for
HIV resistance has been implied by the finding that
among sex worker relatives of the HIV-1 resistant
women, there has been a high degree of interfamily cor-
relation of HIV infection independent of the HLA status
[12]. This suggests that other genes in pathways beyond
the HLA cluster may be key in elucidating the HIV
resistance phenomenon.
A recent preliminary gene expression analysis of HIV
resistant female sex workers who had been in active sex
work for periods of more than seven years and remained
HIV uninfected suggested a high expression of CD26/
dipeptidyl peptidase IV (CD26/DPPIV) a gene coding
for a multifunctional enzyme [13]. Previous studies have
shown however that difference in genetic expression
might not always correspond to similar protein levels
[14]. As high expression of CD26/DPPIV has been
shown previously to inhibit HIV-1 infection in vitro [15]
validating gene expression reports among the HIV resis-
tant female sex workers through protein analysis may
support a quest for further functional studies on CD26/
DPPIV gene as a novel contributor to the HIV resistant
phenotype. In addition, high CD26/DPPIV protein levels
in vivo have been shown to be a risk factor for type 2
diabetes [16]. Incretin hormones involved in insulin sig-
naling have been shown to be degraded by high CD26/
DPPIV levels leading to insulin resistance and
hyperglycemia.
The present study therefore was to confirm if the high
expression of CD26/DPPIV reported at the genetic level
among the HIV resistant sex workers were concordant
with higher peripheral blood protein levels, and whether
this corresponded to clinical type 2 diabetes and
perturbation of other genetic events related to insulin
signaling.
Results
To investigate the level of expression of CD26/dipeptidyl
peptidase IV among HIV highly exposed uninfected sex
workers, we conducted a quantitative DPPIV ELISA on
plasma samples obtained from 100 HIV resistant sex
workers (HIV-R), 100 HIV infected (HIV+) and 100
HIV negative controls (HIV Neg). CD26/DPPIV plasma
concentration was significantly elevated among the HIV-
R group (mean 1315 ng/ml) than the HIV Neg (910 ng/
ml) and HIV + (870 ng/ml, p < 0.001, Figure 1).
To determine whether the observed differences in
soluble plasma expression would correspond to differ-
ences CD26/DPPIV expression on T-cells we carried
out a FACs analysis on peripheral mononuclear cells
derived from the HIV-R, HIV-Neg and HIV+ women.
These data revealed higher CD26/DPPIV expression on
CD4+ T-cells from the HIV-R group when compared to
HIV+ (90.30% vs 80.90 p = 0.002) and HIV Neg
controls (90.30% vs 82.30 p < 0.001) respectively
(Figure 2a). No difference in CD26/DPPIV expression on
CD8+ T cells was observed between the groups (Data not
shown). To further characterise CD26/DPPIV expression
on CD4+ T-cells, we compared the mean fluorescent
intensity (MFI) of CD26/DPPIV expression between
HIV-R, HIV Neg and HIV+. This analysis showed a







Figure 1 Plasma concentrations of Dipeptidyl peptidase IV
enzyme among HIV resistant (HIV-R.) HIV positive (HIV+.) and
HIV negative (HIV neg.) controls (n = 100, each).ELISA (R&D
Systems, Minneapolis MN), was done in duplicate: dilution
factor 1:1000.
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Figure 2b) suggesting that more CD26/DPPIV molecules
are expressed per CD4+T cell in HIV-R subjects.
As high CD26/DPPIV expression has been associated
with type 2 diabetes [16], we next determined the blood
glucose level of HIV-R women (mean age 38.5 ± 5).
Their mean fasting blood sugar level was 5.775 mMol/L
(103 mg/dL, Figure 3). Although this was significantly
higher than the HIV-Neg (4.886 mmol/L or 87.94 mg/
dL p = 0.0061) this was not indicative of clinical Type 2
diabetes mellitus but suggested a prediabetic or
impaired fasting glucose state. The 103 mg/dL of the
mean fasting blood sugar level of HIV-R subjects was
lower than the WHO criteria (110 mg/dL) and slightly
higher than the ADA criteria (100 mg/dL) for the
impaired fasting glucose state [17,18].
To elucidate further the relationship between HIV-R
female sex workers with the diabetic or prediabetic phe-
notype, we investigated the expression patterns of genes
in the insulin signaling pathway which are significantly
perturbed during Type 2 diabetes state. To achieve this
we randomly selected six HIV -R and an equal number
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Figure 2 Increased CD26/DPPIV expression on CD4+ T cells from HIV-R subjects (n=80). A) Representative flow cytometry plots showing
DPP4 expression gated on CD4+ T cell; B) HIV-R have higher expression levels than HIV+ and HIV Neg; C) HIV-R have higher DPP4 mean
florecent intensity than HIV Neg.
p=0.0061
Figure 3 Fasting Blood sugar levels of HIV Resistant (HIV-R)
and HIV negative controls (HIV-Neg),(n = 27 each). Blood
samples were taken and tested using the glucose oxidase test
system (Accu-check, Roche, Basel).
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pared cDNA for gene expression using quantitative real
time PCR analysis. We selected a number of genes from
the insulin signaling pathway and some that had pre-
viously been shown to be related with type 2 diabetes
[19]). Relative expression levels of Insulin receptor sub-
strate 1 (INSR-1), PI4K, AKt, TSC2, NFB, ICOS, LOC6
and Calg were analysed with real time PCR. Figure 4
shows that the differential expression patterns of these
genes are consistent with a type 2 diabetes state. INSR,
located upstream of the insulin pathway and a target of
insulin, was downregulated hence possibly affecting the
downstream events such as, PI4K, AKt and TSC2, Simi-
larly immune regulators previously associated with insu-
lin dysregulation such as NFB, the proinflammatory
cytokine mediator S100/Calgranulin and the inducible
T-cell costimulator ICOS were down expressed in the
HIV-R group compared to the HIV-Neg.
Discussion
CD26/DPPIV is a multifunctional protein ubiquitously
expressed in both soluble and cell surface forms in var-
ious endothelial and epithelial cells including T-cells and
exert it different functions depending on cell type and
conditions it is expressed [20]. It acts as a proteolytic
enzyme, receptor and co-stimulatory protein and its sub-
strates have been reported to be involved in various
physiological process including immunomodulation and
homeostasis. Dysregulation of CD26/DPPIV has been
suggested to result in various pathophysiological process
including rheumatoid arthritis, melanoma and Crohn’s
disease among others [20,21]. Its association with Type 2
diabetes is however well confirmed with DPPIV inhibi-
tors being used worldwide as approved regimens for anti-
type 2 diabetes treatment [22]. Our observation of high
CD26/DPPIV expression, significant down expression of
genes in the insulin signaling pathway and impaired fast-
ing glucose state (IFG) implied an evolving type 2 dia-
betes condition among the HIV resistant commercial sex
workers. The duration for evolution to full type 2 dia-
betes from an IFG state is however controversial. While
some studies indicate that IFG conditions often lead to
diabetes within 3 years, others have suggested a 50% risk
over a ten year period [23]. The Nairobi female sex
worker cohort has been followed up biannually for peri-
ods longer than ten years, and though blood sugar analy-
sis has not been a routine feature, cases of overt Type 2
diabetes has rarely been observed. We postulate that this
population, despite its high CD26/DPPIV levels may not
be at risk of developing type 2 diabetes. There will how-
ever be a need to incorporate type 2 diabetes evaluations
in future follow-up to determine the validity of this asser-
tion taking into account specific DPPIV enzyme activity
which we did not evaluate in this study.
Figure 4 Quantitative RT PCR expression patterns of genes previously associated with Type 2 diabetes and in the insulin signaling
pathway between HIV Resistant (HIV -R and HIV negative controls (HIV-Neg) (n = 6 each). Calg-Calgranulin, ICOS-Inducible T-cell
costimulator, INRS-Insulin receptor substrate 1, LOC6-LOC6 gene, PI4K-phospatidylinositol 4 kinase, Akt-serine/threonine protein kinase, NFkB-
nuclear factor kappa B protein, TSC2-Tuberin.
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sion with HIV resistance is well supported by our data
at the gene, soluble protein and cell surface level, the
mechanism by which it protects against HIV acquisition
remains unclear. One possibility is the key role it plays
in cleaving off dipeptides from amino termini containing
proline or alanine moieties at the penultimate position
[24]. A number of chemokines have been shown to
share this sequence at their termini including RANTES,
an interleukin 8 superfamily chemokine has been shown
to inhibit HIV infection by competing with the virus for
its coreceptor CCR5. Previous data has shown that in
contrast to intact RANTES, a DPPIV truncated
RANTES inhibited in vitro HIV infection of mononuc-
lear cells by M-tropic HIV strains fivefold efficiently
[15,24]. Similarly several workers have shown that HIV
infected subjects have defective CD4+ T cells with a
poor ability to recognize and respond to antigens
[25,26]. Antigen recognition is the preserve of CD4+ T-
cells expressing CD26/DPPIV which proliferate in
response to soluble antigens and activate MHC-
restricted cytotoxic T cells resulting in annihilation of
virally infected cells [20,27]. This has been supported by
findings that antigen response in HIV-1 infected indivi-
duals could be restored by addition of soluble CD26/
DPPIV in vitro, suggesting an important role for CD26/
DPPIV in HIV-specific immunity [28].
The probable mechanism of CD26/DPPIV activity
against HIV acquisition in the Nairobi cohort may how-
ever add a new dimension to the above observations.
Our recent findings indicate a significantly lowered
immune activation state among the HIV-R female sex
workers as compared to HIV negative controls [13,29].
This lowered activation state or immune quiescence has
also been observed among HIV exposed seronegative
partners of HIV infected spouses [7] and HIV unin-
fected hemophiliacs transfused with HIV seropositive
donor blood [30]. The contribution of CD26/DPPIV to
a lowered immune activation state among the HIV-R
female sex workers is puzzling.
There is substantial evidence that CD26/DPPIV can
act as the trigger to immune activation [31-34]. This has
been supported by studies showing that reversible
DPPIV inhibitors suppress proliferation of human
PBMCs s and enhance production of cytokines that
inhibit antigen stimulation of T-cells [35]. Our findings
of high CD26/DPPIV expression in vivo in an environ-
ment of lowered T-cell immune activity is hence intri-
guing. One possible explanation maybe due to the
perturbations of the insulin signaling pathway in these
women which induced the down expression of the
nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-B) and other pro-inflammatory enhancers
(calgranulin and ICOS). NF-B is a protein complex
that regulates the expression of a multitude of immune
response genes including cytokines, chemokines, antigen
presenting cells and adhesion receptors [36]. In response
to a variety of stimuli, including cytokines, viral and
bacterial pathogens, a latent inactive NF-Bc o m p l e xi s
activated in the cytoplasm through phosphorylation and
translocates to the nucleus, where it stimulates tran-
scription of genes. Activation of NFB by the inflamma-
tory cytokine alpha tumor necrosis factor (TNFa)h a s
been shown to involve the phosphotidylinositol pathway
together with its downstream targets-Akt, TSC1 and
TSC2 through IRS 1 [37,38]. Quantitative real time PCR
confirmed low expression in IRS1, PI4K TSC and, NFB
among the HIV resistant female sex workers (Figure 4).
We hypothesize that in presence of high CD26/DPPIV,
the reduced insulin signaling leads to a low activity of
phosphatidylinositol cascade system which in turn
resulted in a lower expression of TSC-2, a build-up of
the MTORC1 and subsequent repression of NFB. In-
depth functional studies will be required to test this
assertion. Our observations suggest that metabolic and
signaling pathways that predispose to an impaired glu-
cose fasting state and Type 2 diabetes may be new cor-
relates of HIV resistance. In addition, it underscores the
key role of a systems biology in discovery of novel can-
didate biological markers that may be crucial in the




The Nairobi (Pumwani) commercial sex worker cohort
was established in 1985 and has provided vital data that
there might be biological mediated resistance to HIV
infection [11,39]. Despite repeated exposures to HIV-1,
a number of women in the cohort have remained HIV
uninfected for long periods and have epidemiologically
been defined as resistant. The definition used in the cur-
rent study were female sex workers actively followed in
the cohort for more than seven years and persistently
seronegative at biannual visits and negative by a sensi-
tive PCR assay for proviral HIV-1 [8]. HIV infected
commercial sex workers who were not on antiretroviral
treatment (HIV+) and HIV negative antenatal clinic
attendees (HIV Neg) were included as controls. Written
Informed consent was sought from all volunteers and
the study received ethical approval from ethical review
boards of University of Nairobi and the Kenya Medical
Research Institute.
Soluble CD26/DPPIV analysis
Peripheral blood samples were randomly obtained from
HIV Resistant and HIV positive female sex workers.
Samples were also obtained from a HIV negative
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for age (38.5 yrs) and race from the same part of Nair-
obi. All samples were separated to yield plasma and per-
ipheral mononuclear cells. Soluble CD26/DPPIV plasma
levels were quantified by Human DPPIV/CD26 Quanti-
kine ELISA kit (R&D Systems, Minneapolis MN) follow-
ing the manufacturer’s recommendation. Briefly,
standards and samples were diluted to a 1:1000 and ran
in triplicate. Optical densities of the standards were
used to generate a standard curve to determine sample
concentration. Mean values were calculated and tests for
significance determined with Graphpad Prism using stu-
dent -t tests. A total of 300 subjects (100 in each arm)
were used for the study.
Cell surface CD26 expression analysis
To determine expression differences at cell surface level
(CD26) a 3 color flow-cytometry (FACs) analysis was
performed with the use of anti-CD26 antibody. PBMC
were stained for CD4, CD8, and DPP4 washed and fixed
using 1% paraformaldehyde. FACS data was analyzed
using FlowJo (Tree Star, Ashland, OR). Lymphocytes
were gated on forward versus side scatter, and then
CD4 versus CD8. CD26/DPPIV expression levels were
analyzed on CD4+ cells. Gates were set on the basis on
single stained samples that did not contain CD26/
DPPIV and used to calculate expression and mean flor-
escent intensity levels. Significant values were deter-
mined in Prism using the Mann Whitney test.
Investigation for clinical type 2 diabetes
To investigate clinical type 2 diabetes, commercial sex
workers who had a significantly elevated soluble CD26/
DPPIV plasma concentration were re-assessed for blood
sugar levels. Identified volunteers were requested to sus-
pend sex work for at least 24 hours and undergo an
overnight fast. Blood samples were obtained before
breakfast and analyzed for blood sugar using the glucose
oxidase test system (Accu-check, Roche, Basel). Volun-
teers with blood glucose levels above 125 mg/dl (6.9
mmol/l) were considered diabetic and those between
100-125 mg/dl considered as having Impaired fasting
glucose state as per the ADA definition criteria [18].
Expression patterns of genes in the insulin/type 2
diabetes signaling pathway
Quantitative PCR analysis of selected genes in the insu-
lin signaling pathway from a representative sample of
HIV-R and HIV-Neg controls were done using Biosys-
tems 7500 Real-Time PCR System (ABI, Foster City,
CA). Assay protocols followed the Quantitect SYBR
Green RTPCR a kit (Qiagen GmbH, Hilden DZ). Briefly
500 ng of total RNA extracted was reverse transcribed
into cDNA using superscript II reverse transcript.
Aliquots of equal amounts of cDNA from each sample
were ran in duplicate and normalized using an internal
control gene 18s RNA. Relative expression of each gene
was determined from a standard curve generated from a
pool of cDNA from the same samples. P-values for sig-
nificance were analyzed using student t-test.
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